| Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy S Gaur, Y Wen, JH Song, NU Parikh, LS Mangala, AM Blessing, C Ivan, ... Oncotarget 6 (30), 29161, 2015 | 120 | 2015 |
| Src signaling pathways in prostate cancer A Varkaris, AD Katsiampoura, JC Araujo, GE Gallick, PG Corn Cancer and Metastasis Reviews 33, 595-606, 2014 | 112 | 2014 |
| The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials A Varkaris, PG Corn, S Gaur, F Dayyani, CJ Logothetis, GE Gallick Expert opinion on investigational drugs 20 (12), 1677-1684, 2011 | 92 | 2011 |
| EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors PENS Vasconcelos, C Gergis, H Viray, A Varkaris, M Fujii, D Rangachari, ... JTO clinical and research reports 1 (3), 100051, 2020 | 65 | 2020 |
| Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma A Varkaris, DW Lewis, FW Nugent Official journal of the American College of Gastroenterology| ACG 112 (12 …, 2017 | 64 | 2017 |
| Ligand‐independent activation of MET through IGF‐1/IGF‐1R signaling A Varkaris, S Gaur, NU Parikh, JH Song, F Dayyani, JK Jin, CJ Logothetis, ... International journal of cancer 133 (7), 1536-1546, 2013 | 57 | 2013 |
| Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma L Hirsch, NM Chanza, S Farah, W Xie, R Flippot, DA Braun, N Rathi, ... JAMA oncology 7 (12), 1815-1823, 2021 | 54 | 2021 |
| Integrating murine and clinical trials with cabozantinib to understand roles of MET and VEGFR2 as targets for growth inhibition of prostate cancer A Varkaris, PG Corn, NU Parikh, E Efstathiou, JH Song, YC Lee, ... Clinical Cancer Research 22 (1), 107-121, 2016 | 51 | 2016 |
| Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival E Bournakis, E Efstathiou, A Varkaris, S Wen, M Chrisofos, C Deliveliotis, ... Anticancer research 31 (4), 1475-1482, 2011 | 50 | 2011 |
| Targeted therapies in multiple myeloma E Kastritis, A Charidimou, A Varkaris, MA Dimopoulos Targeted oncology 4, 23-36, 2009 | 49 | 2009 |
| Modeling of patient-derived xenografts in colorectal cancer A Katsiampoura, K Raghav, ZQ Jiang, DG Menter, A Varkaris, MP Morelli, ... Molecular cancer therapeutics 16 (7), 1435-1442, 2017 | 48 | 2017 |
| MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation S Arai, A Varkaris, M Nouri, S Chen, L Xie, SP Balk Elife 9, e54954, 2020 | 43 | 2020 |
| Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer YC Lee, SC Lin, G Yu, CJ Cheng, B Liu, HC Liu, DH Hawke, NU Parikh, ... Cancer research 75 (22), 4949-4959, 2015 | 41 | 2015 |
| Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? K Sehgal, A Varkaris, H Viray, PA VanderLaan, D Rangachari, DB Costa Journal for immunotherapy of cancer 8 (1), 2020 | 40 | 2020 |
| Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways F Dayyani, NU Parikh, AS Varkaris, JH Song, S Moorthy, T Chatterji, ... PloS one 7 (12), e51189, 2012 | 39 | 2012 |
| Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer I Mountzios, E Bournakis, E Efstathiou, A Varkaris, S Wen, M Chrisofos, ... Urology 77 (3), 682-687, 2011 | 32 | 2011 |
| Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer A Varkaris, A Katsiampoura, JS Davis, N Shah, M Lam, RL Frias, C Ivan, ... British journal of cancer 120 (3), 340-345, 2019 | 31 | 2019 |
| Targeting the intrinsic apoptosis pathway: a window of opportunity for prostate cancer D Westaby, JM Jimenez-Vacas, A Padilha, A Varkaris, SP Balk, ... Cancers 14 (1), 51, 2021 | 22 | 2021 |
| Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells T Chatterji, AS Varkaris, NU Parikh, JH Song, CJ Cheng, RE Schweppe, ... Oncotarget 6 (12), 10175, 2015 | 20 | 2015 |
| WNT5a signaling through ROR2 activates the hippo pathway to suppress YAP1 activity and tumor growth K Wang, F Ma, S Arai, Y Wang, A Varkaris, L Poluben, O Voznesensky, ... Cancer research 83 (7), 1016-1030, 2023 | 12 | 2023 |
